Chronic Stable Angina, Congestive Heart Failure, Essential Hypertension
Conditions
Keywords
Carvedilol, Dilatrend SR capsule, Dilatrend Tablet, Pharmacokinetics, Healthy male subjects
Brief summary
The purpose of this study is to compare the pharmacokinetic characteristics and safety of dilatrend SR capsule 32mg and Dilatrend tablet 25mg in healthy male subjects.
Detailed description
Healthy male subjects are administrated multiple-dose over the period I and II (Crossover) of dilatrend SR capsule 32mg and dilatrend tablet 25mg.
Interventions
DRUGDilatrend SR capsule 32mg
* 1 capsule, oral, once daily, 7days * over the period I&II(crossover)
DRUGDilatrend IR tablet 25mg
* 1 tablet, oral, once daily, 7days * over the period I&II(crossover)
Sponsors
Chong Kun Dang Pharmaceutical
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
20 Years to 35 Years
Healthy volunteers
Yes
Inclusion criteria
* Between 20 aged and 35aged in healthy male * Body Weight more than 50kg, and within 20% of ideal body weight(IBW). * IBW(kg) = {height(cm)-100}\*0.9 * Have not any congenital or chronic disease and medical symptoms. * Suitable results of inspections(laboratory test, ECG, etc) within 21 days before IP administration. * Agreement with written informed consent
Exclusion criteria
* Subject has hypersensitivity reaction or clinically significant history about carvedilol or investigator drug. * Clinically significant cardiovascular system, respiratory system, liver, kidney, endocrine system, gastrointestinal system, central nervous system, blood tumor, mental disease, skin disease, otorhinolaryngologic diseases and so on. * Hypotension(SBP \< 105mmHg or DBP \< 65mmHg), Hypertension(SBP \> 150mmHg or DBP \> 100mmHg) * Heart rate \< 50times/minute * Active liver disease or AST, ALT \> 1.5\*upper limit of normal range * Creatinine clearance \< 80mL/min * Subject has a disease affecting drug's ADME or gastrointestinal surgery. * Subject with symptoms of injured or acute disease within 28days before the first IP administration. * Subject has a history of drug abuse or a positive reaction for drug abuse at the screening test for urine. * Taking ETC medicine including oriental medicine within 14days before the first IP administration or Taking OTC medicine within 7days * Subject takes an abnormal meal which affect the ADME of drug. * Previously participate in other trial within 90days. * Previously make whole blood donation within 60days or component blood donation within 30days before the first IP administration. * Continued to be taking caffeine(caffeine \> 5cup/day), drinking(alcohol \> 21unit/week, 1unit = 10g = 12.5mL of pure alcohol) or during clinical trials can not be drunk or severe heavy smoker(cigarette \> 10cigarettes/day). * Subject with positive reaction about serum test(HBsAg, HCV Ab, HIV Ag/Ab, VDRL) * Genetic problems such as galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption. * An impossible one who participates in clinical trial by investigator's decision including for reason of laboratory test result.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| In the steady state Dilatrend SR Capsule 32mg and Dilatrend tablet 25mg AUCtau | 0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48hr post-dose (on last day of each period) | AUCtau: Area under the plasma concentration-time curve for each dosing interval (from time 0 to 48 hours sample) determined using the linear trapezoidal rule |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| In the steady state Dilatrend SR Capsule 32mg and Dilatrend tablet 25mg Css,max | 0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48hr post-dose (on last day of each period) | Css,max : Maximum drug concentration in plasma determined directly from individual concentration-time data |
| In the steady state Dilatrend SR Capsule 32mg and Dilatrend tablet 25mg Css,min | 0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48hr post-dose (on last day of each period) | Css,min : Minimum drug concentration in plasma determined directly from individual concentration-time data |
| In the steady state Dilatrend SR Capsule 32mg and Dilatrend tablet 25mg AUCinf | 0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48hr post-dose (on last day of each period) | AUCinf: Area Under the Concentration time curve with the last concentration extrapolated based on the elimination rate constant Kel |
| In the steady state Dilatrend SR Capsule 32mg and Dilatrend tablet 25mg t½ | 0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48hr post-dose (on last day of each period) | t½ : Observed terminal elimination half-life |
| Number of participants with adverse events | From 1day to 37 days | * Evaluated safety parameters included: physical examination, vital sign, laboratory test, ECG * adverse event monitoring |
| In the steady state Dilatrend SR Capsule 32mg and Dilatrend tablet 25mg Tss,max | 0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48hr post-dose (on last day of each period) | Tss,max : Time to reach maximum drug concentration in plasma calculated from \[plasma\] versus time profiles |
Countries
South Korea
Contacts
Primary ContactYoung-Ran Yoon
Outcome results
None listed